Clinical trials: Mucosal Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT03033576
- Testing
- Ipilimumab, Nivolumab
- Where
- 638 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Melanoma
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open-label phase II study to assess the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with…
- Trial name
- NCT05420324
- Testing
- YH003, Pembrolizumab, albumin paclitaxel
- Where
- 12 sites in China
- Volunteers
- 20 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Mucosal Melanoma
Molecular Characterization of Primary Mucosal Melanoma
Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new…
- Trial name
- MELMUQ (NCT03319693)
- Testing
- Somatic Genetic
- Where
- France
- Volunteers
- 65 people
- Sponsor
- CHU de Reims
Mucosal Melanoma
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival.
- Trial name
- Neo PeLeMM (NCT05545969)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Australia
- Sponsor
- Melanoma Institute Australia
Cutaneous Melanoma, Mucosal Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7
- Trial name
- NCT02519322
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Acral Lentiginous Melanoma, Mucosal Melanoma
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue…
- Trial name
- NCT02978443
- Testing
- Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Georgetown University
Melanoma, Metastatic Melanoma
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma.
- Conditions
- Melanoma, Metastatic Melanoma, Mucosal Melanoma
- Trial name
- MEL60 (NCT02126579)
- Testing
- Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Craig L Slingluff, Jr
Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune…
- Trial name
- NCT04653038
- Testing
- MGD013
- Where
- 13 sites in China
- Volunteers
- 92 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Recurrent Metastatic Melanoma, Cutaneous Melanoma
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy.
- Conditions
- Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma, Uveal Melanoma
- Trial name
- NCT05482074
- Testing
- Olaparib
- Sponsor
- Dana-Farber Cancer Institute
Melanoma (Skin), Melanoma Stage IV
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1…
- Conditions
- Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
- Trial name
- TIMAR1 (NCT04904120)
- Testing
- [203Pb]VMT01, [68Ga]VMT02
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Perspective Therapeutics
Advanced Mucosal Melanoma
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
This is a phase II, open, single-center study to explore the efficacy and safety of Envafolimab combined with recombinant human endostatin, temozolomide and cisplatin in the treatment of mucosal melanin.
- Trial name
- NCT06041724
- Testing
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- Volunteers
- 46 people
- Sponsor
- Fudan University
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Mucosal Melanoma
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then…
- Trial name
- NCT03241186
- Testing
- Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Robert R. McWilliams, MD
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Melanoma (Skin)
Atypical MOLes and Melanoma Early Detection Study (MoleMed)
This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms.
- Conditions
- Melanoma, Melanoma (Skin), Moles, Nevus
- Trial name
- MoleMed (NCT04353050)
- Testing
- Non-invasive adhesive system (patch)
- Where
- 2 sites in Russia
- Volunteers
- 350 people
- Sponsor
- Russian Academy of Medical Sciences
Mucosal Melanoma
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized…
- Trial name
- NCT04180995
- Testing
- TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Mucosal Melanoma
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely resected, Toripalima Combined with…
- Trial name
- NCT04462965
- Testing
- Toripalimab, Temozolomide
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Melanoma, Sinonasal Melanoma
Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM
Sinonasal mucosal melanoma (SNMM) is a very rare tumor, and SNMM is highly aggressive in nature, with a 5-year survival rate of about 20~30%.
- Trial name
- SNMM (NCT05009446)
- Testing
- endoscopic surgery, intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy, Chemotherapy drug
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Eye & ENT Hospital of Fudan University